Associations among plasma concentrations of regorafenib and its metabolites, adverse events, and ABCG2 polymorphisms in patients with metastatic colorectal cancers
ConclusionThis study showed that theCtrough of regorafenib was associated with bilirubin increase, and also clarified for the first time that theCtrough of M5 was significantly correlated with hypertension and severe rash.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Bilirubin | Cancer | Cancer & Oncology | Chemotherapy | Colorectal Cancer | Drugs & Pharmacology | Genetics | Hypertension | Study